71. Pertussis
Thursday, October 3, 2013: 2:00 PM-3:30 PM
Room: The Moscone Center: 134 (Hall E)

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe the changing epidemiology of pertussis in the United States and approaches to managing disease
  • discuss the immune response to whole cell and acellular pertussis vaccines and their impact on future disease prevention
  • outline the pathways, mechanisms and barriers to developing and implementing improved pertussis vaccines

Target Audience: vaccinologists, scientists, researchers, public health practitioners, pharmacists, nurses, microbiologists, members-in-training, medical students and residents, investigators, infectious diseases physicians, infectious diseases pediatricians, infection preventionists, hospital epidemiologists, health care workers, fellows, epidemiologists, clinicians, academicians, immunologists

Tracks: Pediatric ID, Investigative ID, Global ID, Epidemiology and Infection Control, Adult ID

Moderator:  Ruth Lynfield, MD, Minnesota Department of Health

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-13-096-L01-P


R. Lynfield, None

S. A. Plotkin, Sanofi Pasteur: Consultant, Consulting fee
GSK: Consultant, Consulting fee
Many other vaccine manufacturers: Consultant, Consulting fee

R. Lynfield, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.